インターベンショナルオンコロジーアブレーションの世界市場

インターベンショナルオンコロジーアブレーションの世界市場は2030年までに8億8,400万米ドルに達する見込み

2024年に5億6,320万米ドルと推定されるインターベンショナルオンコロジーアブレーションの世界市場は、2030年には8億8,400万米ドルに達し、分析期間2024-2030年のCAGRは7.8%で成長すると予測されます。本レポートで分析したセグメントの1つである高周波アブレーションは、CAGR 9.1％を記録し、分析期間終了までに4億6,950万米ドルに達すると予測されています。マイクロ波アブレーションセグメントの成長は、分析期間でCAGR 5.4%と推定されます。

米国市場は1億5,340万米ドルと推定、中国はCAGR12.4%で成長予測

米国のインターベンショナルオンコロジーアブレーション市場は、2024年に1億5,340万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億9,080万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは12.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.8%と7.6%と予測されています。欧州では、ドイツがCAGR 5.2%で成長すると予測されています。

世界のインターベンショナルオンコロジーアブレーション市場- 主要動向と促進要因のまとめ

インターベンショナルオンコロジーアブレーションががん治療の重要なモダリティとして台頭している理由とは？

インターベンショナルオンコロジーアブレーションは、固形腫瘍の低侵襲治療において、従来の外科的切除や全身療法に代わる局所的な画像誘導による不可欠な治療アプローチとなっています。この技術は、開腹手術を必要とせずにがん組織を破壊するために、高周波（RF）、マイクロ波、冷凍アブレーション、不可逆的エレクトロポレーションなどのエネルギーベースの装置を使用します。肝臓、肺、腎臓、骨、軟部組織腫瘍の患者に最も頻繁に使用され、特に腫瘍の位置、大きさ、患者の合併症のために手術が不可能な場合に使用されます。

超音波、CT、MRIなどのモダリティを用いたインターベンショナルオンコロジーアブレーションの精度は、健常な周辺組織を温存しながら標的治療を可能にします。化学療法や免疫療法のような全身療法との併用や、移植や手術への橋渡しとして使用されることが多くなっています。早期回復、合併症の減少、コスト削減を伴う、侵襲の少ない外来ベースのがん治療への需要により、腫瘍切除術は早期または乏転移性疾患管理における好ましい選択肢となっています。

インターベンショナル・オンコロジーにおける腫瘍焼灼術の能力を向上させる技術とは？

インターベンショナルオンコロジーアブレーションこの分野は、特にアブレーション装置の設計、画像誘導システム、熱制御アルゴリズムにおいて、著しい技術的進歩の途上にあります。マイクロ波アブレーションシステムは、RFアブレーションよりも高い温度と速いアブレーション時間を達成する能力で知られ、大きく深い腫瘍の治療でますます好まれています。クライオアブレーションシステムは治療中の可視化を向上させ、腎腫瘍や前立腺腫瘍のように正確な断端が重要な場合にしばしば使用されます。

リアルタイムの3Dナビゲーション、造影超音波、MRサーモメトリーなどの高度な画像誘導技術は、アブレーションの精度と手技の安全性を向上させています。ロボット工学やAIを駆使したソフトウェア・プラットフォームの革新もまた、より予測可能な結果を可能にし、経皮的に治療できる腫瘍の複雑性を拡大しています。さらに、電極の設計、冷却機構、マルチプローブの同期化などの開発により、腫瘍の被覆率の向上、再発率の低下、複数の病変を同時に治療できるようになりつつあります。

不可逆的エレクトロポレーション（IRE）のような非熱的切除法の研究も進んでいます。IREは電気パルスを用いて細胞膜を透過させ、大きな加熱を伴わずにアポトーシスを誘導するもので、胆管や血管のような重要な構造に近い腫瘍に適しています。このような選択肢の拡大により、インターベンショナル腫瘍学治療の範囲と安全性が広がっています。

どのような患者集団と臨床環境が切除療法の採用を促進しているか？

切除不能または内科的に手術不可能な腫瘍を有する患者が、インターベンショナルオンコロジーアブレーションの主要な候補です。このアプローチは肝細胞がん（HCC）および大腸がんからの肝転移で一般的に採用されており、早期の疾患では治癒の可能性があり、進行した症例では緩和効果があります。肺および腎腫瘍も、特に手術が不可能な合併症を有する患者において、経皮的アブレーションを使用して管理されることが多いです。

腫瘍センター、三次病院、外来インターベンショナルラジオロジー診療所がアブレーション治療の主な舞台です。集学的がん治療チームへのインターベンショナルオンコロジーの統合が進み、アブレーションが手術、全身療法、放射線療法を補完することで、より広範な導入が促進されています。多くのヘルスケアシステムにおいて、画像診断、低侵襲インフラ、専門医トレーニングへのアクセスが向上しており、手技の導入が進んでいます。さらに、個別化された低外傷の治療選択肢を求める患者のニーズは、より侵襲的な介入よりもアブレーションへの嗜好をシフトさせています。

インターベンショナルオンコロジーアブレーション市場の成長はいくつかの要因によってもたらされる...

インターベンショナルオンコロジーアブレーション市場の成長は、世界のがん罹患率の上昇、低侵襲治療に対する需要の増加、画像誘導介入の技術革新など、いくつかの要因によってもたらされます。がん治療が個別化、標的化、より破壊的でない治療パラダイムへと進化する中、アブレーションは従来の外科手術の候補でない患者や全身毒性を避けたい患者にとって説得力のある解決策を提供します。熱および非熱アブレーション技術の進歩により、治療可能な腫瘍の範囲が拡大し、治癒的および緩和的な環境における転帰が改善されつつあります。

ヘルスケアシステムはアブレーションの費用対効果をますます認識するようになっており、特に外来やデイケアの環境では、入院の減少や回復の早さが経済的な大幅な節約につながります。診療報酬の改善、新しい機器の規制当局による承認、主要な治療ガイドラインへのアブレーションの採用は、市場の採用をさらに加速させています。さらに、免疫腫瘍薬との併用療法の一環としてアブレーションが使用されるようになったことで、がん治療の新境地が開かれつつあります。インターベンショナル腫瘍学が主流の腫瘍学経路に組み込まれるにつれ、腫瘍切除術は今後数年間、世界的に力強く拡大するものと思われます。

セグメント

技術（ラジオ波アブレーション、マイクロ波アブレーション、クライオアブレーション、非可逆的エレクトロポレーションアブレーション）;適応症（肝がん、腎臓がん、肺がん、その他の適応症）;エンドユーザー（病院＆クリニック、外来手術センター、その他のエンドユーザー）

調査対象企業の例（全34件）

• Abbott Laboratories
• AngioDynamics
• Boston Scientific Corporation
• CASCINATION AG
• Cook Medical
• DFINE, Inc.
• EDAP TMS S.A.
• GE HealthCare
• HealthTronics
• Intuitive Surgical
• Medtronic plc
• Merit Medical Systems, Inc.
• Profound Medical
• STARmed Co., Ltd.
• Stryker Corporation
• Teleflex Incorporated
• Terumo Corporation
• Varian Medical Systems（now part of Siemens Healthineers）
• Visionect d.o.o.
• ZAP Surgical Systems, Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Interventional Oncology Ablation Market to Reach US$884.0 Million by 2030

The global market for Interventional Oncology Ablation estimated at US$563.2 Million in the year 2024, is expected to reach US$884.0 Million by 2030, growing at a CAGR of 7.8% over the analysis period 2024-2030. Radiofrequency Ablation, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$469.5 Million by the end of the analysis period. Growth in the Microwave Ablation segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$153.4 Million While China is Forecast to Grow at 12.4% CAGR

The Interventional Oncology Ablation market in the U.S. is estimated at US$153.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$190.8 Million by the year 2030 trailing a CAGR of 12.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

Global Interventional Oncology Ablation Market - Key Trends & Drivers Summarized

Why Is Interventional Oncology Ablation Emerging as a Critical Modality in Cancer Treatment?

Interventional oncology ablation has become an essential therapeutic approach in the minimally invasive treatment of solid tumors, offering a localized, image-guided alternative to traditional surgical resection and systemic therapies. This technique involves the use of energy-based devices-such as radiofrequency (RF), microwave, cryoablation, and irreversible electroporation-to destroy cancerous tissues without the need for open surgery. It is most frequently used for patients with liver, lung, kidney, bone, and soft tissue tumors, particularly when surgery is not feasible due to tumor location, size, or patient comorbidities.

The precision of interventional oncology ablation, guided by modalities such as ultrasound, CT, or MRI, enables targeted treatment while sparing healthy surrounding tissue. It is increasingly used in combination with systemic therapies like chemotherapy and immunotherapy, or as a bridge to transplantation or surgery. The demand for less invasive, outpatient-based cancer treatments with faster recovery, fewer complications, and cost savings is making tumor ablation a preferred option in early-stage or oligometastatic disease management.

What Technologies Are Advancing the Capabilities of Tumor Ablation in Interventional Oncology?

The interventional oncology ablation field is undergoing significant technological advancement, particularly in ablation device design, image-guidance systems, and thermal control algorithms. Microwave ablation systems, known for their ability to achieve higher temperatures and faster ablation times than RF ablation, are increasingly favored in treating large and deep-seated tumors. Cryoablation systems provide enhanced visualization during treatment and are often used where precision margins are critical, such as in renal or prostate tumors.

Advanced image-guidance technologies-including real-time 3D navigation, contrast-enhanced ultrasound, and MR thermometry-are improving ablation accuracy and procedural safety. Innovations in robotics and AI-driven software platforms are also enabling more predictable outcomes and expanding the complexity of tumors that can be treated percutaneously. Furthermore, developments in electrode design, cooling mechanisms, and multiprobe synchronization are supporting better tumor coverage, reduced recurrence rates, and the ability to treat multiple lesions simultaneously.

Research is also progressing in non-thermal ablation modalities, such as irreversible electroporation (IRE), which uses electrical pulses to permeabilize cell membranes and induce apoptosis without significant heating-making it suitable for tumors near critical structures like bile ducts and blood vessels. These expanding options are broadening the scope and safety of interventional oncology treatments.

Which Patient Populations and Clinical Settings Are Driving Adoption of Ablative Therapies?

Patients with unresectable or medically inoperable tumors are the primary candidates for interventional oncology ablation. The approach is commonly adopted in hepatocellular carcinoma (HCC) and liver metastases from colorectal cancer, where it offers curative potential in early-stage disease and palliative benefits in advanced cases. Lung and kidney tumors are also frequently managed using percutaneous ablation, especially in patients with comorbidities that preclude surgery.

Oncology centers, tertiary hospitals, and outpatient interventional radiology clinics are major settings for ablation procedures. Growing integration of interventional oncology into multidisciplinary cancer care teams is facilitating broader adoption, where ablation complements surgery, systemic therapy, and radiotherapy. In many healthcare systems, increasing access to diagnostic imaging, minimally invasive infrastructure, and specialist training is enhancing procedural uptake. Moreover, patient demand for personalized, low-trauma treatment options is shifting preferences toward ablation over more invasive interventions.

The Growth in the Interventional Oncology Ablation Market Is Driven by Several Factors…

The growth in the interventional oncology ablation market is driven by several factors including rising global cancer incidence, increasing demand for minimally invasive therapies, and technological innovation in image-guided intervention. As oncology care evolves toward personalized, targeted, and less disruptive treatment paradigms, ablation offers a compelling solution for patients who are not candidates for traditional surgery or wish to avoid systemic toxicity. Advances in thermal and non-thermal ablation technologies are expanding the range of treatable tumors and improving outcomes in both curative and palliative settings.

Healthcare systems are increasingly recognizing the cost-effectiveness of ablation, particularly in outpatient and day-care settings, where reduced hospitalization and faster recovery translate into significant economic savings. Reimbursement improvements, regulatory approvals of new devices, and the inclusion of ablation in major treatment guidelines are further accelerating market adoption. Additionally, the increasing use of ablation as part of combination therapy with immuno-oncology agents is opening new frontiers in cancer treatment. As interventional oncology becomes more integrated into mainstream oncology pathways, tumor ablation is poised for robust global expansion in the coming years.

SCOPE OF STUDY:

The report analyzes the Interventional Oncology Ablation market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation); Indication (Liver Cancer, Kidney Cancer, Lung Cancer, Other Indications); End-User (Hospitals & Clinics, Ambulatory Surgery Centers, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbott Laboratories
• AngioDynamics
• Boston Scientific Corporation
• CASCINATION AG
• Cook Medical
• DFINE, Inc.
• EDAP TMS S.A.
• GE HealthCare
• HealthTronics
• Intuitive Surgical
• Medtronic plc
• Merit Medical Systems, Inc.
• Profound Medical
• STARmed Co., Ltd.
• Stryker Corporation
• Teleflex Incorporated
• Terumo Corporation
• Varian Medical Systems (now part of Siemens Healthineers)
• Visionect d.o.o.
• ZAP Surgical Systems, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Interventional Oncology Ablation - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Cancer Incidence Propels Demand for Minimally Invasive and Targeted Tumor Ablation Techniques
  • Increasing Adoption of Image-Guided Interventional Oncology Supports Growth of Thermal and Non-Thermal Ablation Procedures
  • Technological Advancements in Radiofrequency, Microwave, and Cryoablation Devices Enhance Precision and Treatment Outcomes
  • Shift Toward Day-Care and Outpatient Oncology Models Strengthens the Business Case for Non-Surgical Tumor Ablation
  • Growing Clinical Preference for Organ-Preserving Therapies Fuels Use of Ablation in Early-Stage and Non-Resectable Tumors
  • Improved Access to Advanced Imaging Modalities Drives Wider Use of Image-Guided Tumor Localization in Ablation Procedures
  • Integration of Interventional Oncology Into Multidisciplinary Cancer Care Expands Application Scope in Liver, Kidney, Lung, and Bone Tumors
  • Rising Demand for Repeatable and Low-Morbidity Therapies Encourages Adoption of Ablation Over Radiation or Systemic Therapies
  • FDA Approvals and Expanding Clinical Guidelines Boost Market Confidence in Interventional Ablation as a Standard of Care
  • Advancements in Ablation Applicators and Energy Delivery Systems Enhance Control, Accuracy, and Real-Time Feedback
  • Rise of Robotic and AI-Enhanced Image Navigation Systems Improves Targeting Accuracy and Minimizes Complications in Ablation
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Interventional Oncology Ablation Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Interventional Oncology Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Interventional Oncology Ablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Radiofrequency Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Radiofrequency Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Radiofrequency Ablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Microwave Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Microwave Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Microwave Ablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Cryoablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Cryoablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Cryoablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Irreversible Electroporation Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Irreversible Electroporation Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Irreversible Electroporation Ablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Liver Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Kidney Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Kidney Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Kidney Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• JAPAN
  • Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• CHINA
  • Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• EUROPE
  • Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Interventional Oncology Ablation by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Interventional Oncology Ablation by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• FRANCE
  • Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• GERMANY
  • Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Interventional Oncology Ablation by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Interventional Oncology Ablation by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• INDIA
  • Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Interventional Oncology Ablation by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Interventional Oncology Ablation by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Interventional Oncology Ablation by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Interventional Oncology Ablation by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
• AFRICA
  • Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030

IV. COMPETITION